FDA warns Irvine, CA-based Nihon Kohden Digital Health Solutions that it is marketing an adulterated and misbranded unapproved medical device.
Witnesses at a House Energy and Commerce Health Subcommittee hearing urge lawmakers to modernize the nation's clinical trial system, and strengthen FDA’s scientific capacity to offset China’s rapidly growing share of early-stage drug development.
FDA warns Irvine, CA-based Nihon Kohden Digital Health Solutions that it is marketing an adulterated and misbranded unapproved medical device.
Witnesses at a House Energy and Commerce Health Subcommittee hearing urge lawmakers to modernize the nation's clinical trial system, and strengthen FDA’s scientific capacity to offset China’s rapidly growing share of early-stage drug development.
House Energy and Commerce Health Subcommittee leaders reveal differing views over whether the Trump administration's policies are strengthening or undermining the nation's drug development enterprise.
FDA acting commissioner Kyle Diamantas positions the agency’s four public health pillars as a means to fulfill its enduring mission in a new era.
